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Purpose: To compare the diurnal intraocular pressure (IOP)-lowering efficacy and safety of 
travoprost 0.004% and tafluprost 0.0015% administered to patients with primary open-angle 
glaucoma or ocular hypertension.
Methods: This was a randomized, double-masked, active-controlled, crossover design trial, in 
which patients were randomized to either travoprost or tafluprost monotherapy administered once 
daily in the evening for six weeks and then crossed over to the alternative treatment for another 
six weeks. Diurnal IOP was measured (8 am to 8 pm, every two hours) and a solicited symptom 
survey was administered at the end of both six-week periods, as was conjunctival hyperemia and 
visual acuity assessment, slit-lamp biomicroscopy, and adverse event solicitation.
Results: Fifty-one patients were randomized and 48 patients completed the study. The 12-hour 
mean diurnal IOP was significantly lower with travoprost therapy than with tafluprost therapy 
(P = 0.01), and a significantly lower IOP was also reported for travoprost at five of the seven 
individual time points (P , 0.05). Neither therapy produced a significant increase from baseline 
in any of the individual patient-reported symptom scores, except for hyperemia (P # 0.01), 
which was increased with both treatments. Investigator-observed hyperemia was also increased 
from baseline with both therapies (P , 0.01), although the increase with travoprost therapy 
was significantly smaller than with tafluprost (P , 0.01). No additional safety concerns were 
noted from slit-lamp biomicroscopy or visual acuity results, and no difference was noted in 
patient-reported tolerability of the two medications.
Conclusion: Travoprost 0.004% monotherapy produced lower diurnal IOP than tafluprost 
0.0015% in patients with primary open-angle glaucoma or ocular hypertension and exhibited 
a similar safety profile.
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Introduction
Elevated intraocular pressure (IOP) is considered a key risk factor for the progression 
of glaucoma.1,2 As such, IOP reduction is a primary objective of the pharmacologic 
treatment of glaucoma.3 Several studies have demonstrated that IOP reduction does, 
in fact, slow glaucoma progression.4–6
Prostaglandin analogs are among the most potent IOP-lowering therapies   currently 
available.3 These include latanoprost, travoprost, tafluprost, and bimatoprost. Prostaglandin 
analogs have demonstrated greater IOP-lowering efficacy than beta-adrenergic blockers7 
and, for that reason, are commonly used as first-line therapy against glaucoma.3 In addi-
tion, all prostaglandin analogs have convenient once-daily dosing, whereas some other Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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IOP-lowering therapies require dosing two to three times daily. 
In 1996, latanoprost 0.005% (Xalatan®; Pfizer, New York, NY) 
was the first prostaglandin analog to be approved by the US Food 
and Drug Administration for the treatment of ocular hyperten-
sion and open-angle glaucoma. Travoprost 0.004% (Travatan®; 
Alcon Laboratories Inc, Fort Worth, TX), another prostaglandin 
analog, was approved in 2001 for a similar indication.8 Tafluprost 
0.0015% (Taflotan®; Santen Oy, Tampere, Finland) is the most 
recently released prostaglandin analog, being approved in Europe 
in 2008 but not yet approved in the US.
It is well established that IOP is subject to circadian varia-
tion in both healthy individuals and those with glaucoma, 
although IOP fluctuation is magnified in glaucomatous 
eyes.9 Thus, effective once-daily IOP-lowering medications 
must have consistent efficacy throughout the day to reduce 
the risk of IOP spikes, which have been associated with the 
progression of glaucoma.10 Travoprost 0.004% has not only 
demonstrated significant reductions in IOP throughout a 
24-hour period but also it has shown superior late afternoon 
(4 pm and 6 pm) efficacy compared with that of latanoprost 
0.005%.11,12 Data from a Phase III trial suggest that tafluprost 
0.0015% may have efficacy similar to that of latanoprost.13 
Thus, because of the apparent superiority of IOP control 
by travoprost over latanoprost in the late afternoon, it is 
  reasonable to speculate that travoprost and tafluprost may 
show a pattern of IOP-lowering efficacy that is similar to 
that of travoprost and latanoprost. However, due to the recent 
addition of tafluprost to the marketplace, limited clinical 
information currently exists directly comparing tafluprost 
with other prostaglandin analogs. The aim of the current study 
was to compare the diurnal IOP-lowering efficacy and safety 
of travoprost 0.004% and tafluprost 0.0015% in patients with 
primary open-angle glaucoma or ocular hypertension.
Methods
This was a randomized, double-masked, active-controlled, 
crossover design in which patients were randomized to either 
travoprost or tafluprost monotherapy administered once daily 
in the evening for six weeks and were then crossed over to the 
alternative treatment for another six weeks. The protocol was 
approved by all relevant institutional review boards and the 
study was performed in compliance with the ethical principles 
of the Declaration of Helsinki and Good Clinical Practice. All 
participating patients provided written informed consent.
Patients
Eligible patients were at least 21 years old with a clini-
cal diagnosis of primary open-angle glaucoma or ocular 
  hypertension in at least one eye. Patients on IOP-lowering 
therapy at screening must have required a change in therapy, 
in the investigator’s opinion, to improve efficacy, tolerability, 
or compliance. They also had to have an IOP . 21 mmHg 
in at least one eye at 8 am, $19 mmHg in the same eye at 
4 pm, and , 35 mmHg in both eyes at all diurnal time points 
at the baseline visit. In addition, IOPs in both eyes had to be 
considered safe by the investigator to ensure clinical stabil-
ity of the visual field and optic nerve throughout the study. 
Patients were required to have a best-corrected Snellen visual 
acuity (BCVA) of at least 20/200 in both eyes.
Patients were excluded if they met any of the following 
criteria: the presence of extreme narrow angle with complete 
or partial closure in either eye, except for occludable angles 
treated with a patent iridectomy; any abnormality preventing 
reliable applanation tonometry in qualifying eye(s); any opac-
ity or patient uncooperativeness that would restrict adequate 
examination of the ocular fundus or anterior chamber of either 
eye; concurrent infectious/noninfectious conjunctivitis, kera-
titis, or uveitis in either eye; intraocular conventional surgery 
or laser surgery in qualifying eye(s) within three months prior 
to screening; the risk of visual field or visual acuity worsening 
as a consequence of participation in the trial, in the investiga-
tor’s opinion; progressive retinal or optic nerve disease from 
any cause other than glaucoma; women who were pregnant, 
lactating, or of childbearing potential and not using reliable 
means of birth control; any clinically significant, serious, or 
severe medical or psychiatric condition; any condition that, in 
the investigator’s opinion, would interfere with optimal par-
ticipation in the study or present a special risk to the patient; 
participation in any other investigational study within 30 days 
prior to baseline visit; known history of allergy or sensitivity 
to any components of the study medications that was deemed 
to be clinically significant, in the investigator’s opinion; use 
of systemic medications known to affect IOP that have not 
been on a stable course for seven days prior to the baseline 
visit or an anticipated change in the dosage during the course 
of the study; an unwillingness to accept the risk of iris, skin, 
or eyelash changes associated with prostaglandin therapy; a 
history or risk of uveitis or cystoid macular edema; a history 
of ocular herpes simplex; and anticipated use of systemic 
corticosteroids, by any route except inhaled, for more than 
two weeks during the trial.
Study design
Patients who were eligible for trial participation after 
screening began to wash out their current IOP-lowering 
medications for the following durations: six weeks for Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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prostaglandin analogs and beta-adrenergic blockers, five 
weeks for alpha-adrenergic blockers, four weeks for epineph-
rine-related medications, and two days for pilocarpine or 
carbonic anhydrase inhibitors. At the baseline visit, patients 
underwent IOP measurements using Goldmann applanation 
tonometry every two hours, beginning at 8 am and ending 
at 8 pm (prior to   dosing), in order to create an IOP diurnal 
curve. In addition, at the 8 am baseline visit, patients com-
pleted a symptom survey and underwent bilateral BCVA and 
hyperemia assessments, bilateral slit-lamp biomicroscopy, 
and urine pregnancy testing (for women of childbearing 
potential). The symptom survey queried patients on the fol-
lowing symptoms using a scale of 0 to 4: light sensitivity, 
blurred/dim vision, stinging/burning, foreign body sensa-
tion, pain, and hyperemia. It also included a question about 
the tolerability of the study medications using a scale of 0 
(complete comfort) to 7 (worst pain imaginable) that was 
not administered at the baseline visit.
Patients who remained eligible for participation after 
the baseline examination were randomized to receive 
either travoprost ophthalmic solution 0.004% or tafluprost 
0.0015% for the first six weeks, after which the first study 
medication was discontinued and the other study medication 
was initiated and continued for another six weeks. Patients 
were instructed on how to use their study medication, ie, one 
drop in study eye(s) daily at 8 pm. Measures conducted at 
the week 6 and week 12 visits included a solicited symptom 
survey, bilateral IOP diurnal curve, bilateral BCVA, hype-
remia assessment, and bilateral slit-lamp biomicroscopy. 
Adverse events were collected, monitored, and evaluated 
throughout the study.
Statistics
The primary efficacy variable was mean IOP at 8 pm, and was 
measured by a repeated-measures analysis using a matched-
pairs platform. Assuming a standard deviation of 2.8 mmHg 
and an enrollment of 40 patients, this study was designed 
to provide an 80% power to detect a 1.25 mmHg difference 
between therapies. Secondary efficacy variables were also 
evaluated by repeated-measures analysis. Individual time 
points were analyzed using a paired t-test within the repeated-
measures analysis. A modified Bonferroni correction (α/3) 
adjusted the level to declare significance for individual time 
points analyses. Other variables, including solicited symptom 
survey questions, hyperemia, and visual acuity, were   analyzed 
by a paired t-test. An appropriate modified Bonferroni 
  correction (α/5) adjusted the P value to declare significance 
on the symptom survey. Adverse events were evaluated by a 
McNemar test. The data were analyzed by PRN Pharmaceuti-
cal Research Network, LLC (Dallas, TX).
Results
Fifty-one patients were randomized. Forty-eight patients with 
92 qualifying eyes completed the study and were included in 
the intent-to-treat population. Table 1 shows that patients had 
a mean age of 68.8 years and 60.8% were female.
As presented in Table 2, the 12-hour mean diurnal IOP 
was significantly lower with travoprost than with tafluprost 
(16.9 mmHg versus 17.5 mmHg; P = 0.01); a significantly 
lower IOP was also reported for travoprost at five of the 
seven individual time points (P , 0.05), including at 8 pm 
(P = 0.01), which was the primary endpoint of the study. 
Both therapies produced a similar pattern of IOP control, 
with peak IOP reductions observed at the first time point, 
12 hours after dosing, and trough reductions noted at 4 pm, 
20 hours after dosing (Figure 1).
Neither therapy produced a significant increase from 
baseline in any of the individual symptom scores (light 
sensitivity, blurred/dim vision, stinging/burning, foreign 
body sensation, or pain), except for hyperemia, which was 
increased with both therapies (P # 0.01, Table 3). Investi-
gator-observed hyperemia was also significantly increased 
from baseline for both travoprost (0.26 ± 0.56, P , 0.01) 
and tafluprost (0.42 ± 0.54, P , 0.01), although the increase 
with travoprost therapy was significantly smaller than with 
tafluprost (P , 0.01). Aside from hyperemia, conjunctival 
edema, corneal clarity, lens clarity, and lid erythema, no 
changes from baseline were observed in most measures 
assessed with slit-lamp biomicroscopy. Visual acuity was not 
significantly changed with either travoprost (0.01 ± 0.02) or 
tafluprost (0.00 ± 0.02) treatment (P = 0.49). No significant 
difference was noted in patient-reported tolerability between 
travoprost (0.90 ± 0.31) and tafluprost (0.96 ± 0.20) therapies 
(P = 0.18). One patient experienced a mild headache believed 
not to be   treatment-related while on tafluprost therapy, but 
no other adverse events were reported.
Table 1 Patient demographics of the safety population
Demographic Total  
N = 51
gender (%)
  Male 39.2
  Female 60.8
Age (mean ± SD, years) 68.8 ± 9.0
race (%)
  Caucasian 100
Abbreviation: SD, standard deviation.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Discussion
This is the first published clinical trial that has compared 
treatment with travoprost 0.004% with that of tafluprost 
0.0015%. In this crossover study of patients with primary 
open-angle glaucoma or ocular hypertension, both travoprost 
and tafluprost demonstrated excellent IOP control,   showing 
a mean 7.6 mmHg IOP reduction for travoprost and a mean 
7.1 mmHg IOP reduction from baseline for tafluprost. 
However, travoprost not only produced a significantly lower 
12-hour mean IOP but also exhibited significant reduc-
tions at five of the seven individual time points, with the 
two   nonsignificant time points demonstrating trends toward 
statistical significance. These data suggest that travoprost pro-
vides a modest but significant advantage in IOP control over 
tafluprost. Of note is the fact that, similar to previous studies 
comparing travoprost and latanoprost,11,12 travoprost in this 
study produced superior IOP control in the late afternoon 
(ie, at 4 pm and 6 pm). The difference between this study 
and the previous latanoprost studies is that the significantly 
greater hypotensive effect demonstrated by travoprost was 
not restricted to those time points; rather, it was exhibited at 
all but two of the diurnal time points.
No unexpected safety concerns with either travoprost or 
tafluprost monotherapy were observed during the course of 
this clinical trial. Hyperemia is a class effect of prostaglandin 
analogs,14 and both travoprost and tafluprost induced similarly 
modest levels of hyperemia. Ocular side effects common to 
topical ophthalmic medications, including light sensitivity, pain, 
and foreign body sensation, were minimally reported by patients, 
with mean scores of all side effects surveyed , 0.3 on a scale of 
0 to 4. Moreover, no differences in patient-reported tolerability 
were noted, suggesting that travoprost and tafluprost have similar 
safety and tolerability profiles in this patient population.
This clinical trial with its crossover design and washout 
period for previous IOP-lowering medications was well 
controlled, but it did have some limitations. It was designed to 
provide only six weeks of treatment with each study   medication, 
which makes it challenging to identify any long-term efficacy 
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Figure 1 Decrease in diurnal IOP from baseline produced by travoprost and tafluprost. (intent-to-treat population, N = 48).
Note: *Travoprost showed a significantly larger decrease in IOP from baseline than tafluprost (P , 0.05).
Abbreviation: iOP, intraocular pressure.
Table 2 Mean intraocular pressure at baseline and after six weeks 
of  therapy  with  travoprost  and  tafluprost  (intent-to-treat 
population, n = 48)
Hour Baseline IOP  
(mean ± SD)
Travoprost IOP  
(mean ± SD)
Tafluprost  
IOP  
(mean ± SD)
P value
8 AM 25.9 ± 2.45 17.0 ± 2.36 17.5 ± 2.20 0.06
10 AM 25.0 ± 3.08 16.7 ± 2.39 17.3 ± 2.50 0.02a
12 PM 24.3 ± 3.47 16.7 ± 2.47 17.2 ± 2.46 0.01a
2 PM 23.9 ± 3.22 16.9 ± 2.69 17.3 ± 2.77 0.09
4 PM 24.1 ± 3.06 17.1 ± 2.85 17.6 ± 2.80 0.01a
6 PM 24.1 ± 2.90 16.9 ± 3.12 17.6 ± 3.13 <0.01a
8 PM 24.3 ± 3.35 17.1 ± 3.17 17.7 ± 3.23 0.01a
12-hour mean24.5 ± 2.89 16.9 ± 2.59 17.5 ± 2.62 0.01a
Note: aBolded P values represent statistical significance.
Abbreviations: iOP, intraocular pressure; SD, standard deviation.Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1463
Travoprost 0.004% versus tafluprost 0.0015%
and safety differences between   travoprost and tafluprost. Also, 
although the differences in mean IOP between travoprost 
and tafluprost were statistically significant, they were small 
(0.4–0.7 mmHg). Although the clinical significance of the 
superior IOP control by travoprost is unclear, Konstas et al 
have demonstrated that small differences in IOP (in 1 mmHg 
increments) can have a substantial impact on the likelihood of 
glaucoma progression within certain IOP ranges.15
Conclusion
Travoprost 0.004% monotherapy administered once daily 
in the evening produced superior IOP control throughout a 
12-hour period compared with tafluprost 0.0015% in patients 
with primary open-angle glaucoma or ocular hypertension. 
Travoprost and tafluprost exhibited similar safety and toler-
ability profiles.
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Table 3 Mean change from baseline on the symptom survey scores (based on a scale of 0–4) after six weeks of therapy with travoprost 
and tafluprost (intent-to-treat population, N = 48)
Question Travoprost  
(mean ± SD)
P value Tafluprost  
(mean ± SD)
P value
Do you experience pain in or around your eyes when exposed to light?   0.02 ± 0.25 0.57   0.06 ± 0.24 0.08
Do you experience blurred or dim vision? -0.02 ± 0.33 0.66 -0.02 ± 0.33 0.66
Do you experience stinging or burning?   0.02 ± 0.44 0.74   0.04 ± 0.50 0.57
Do you feel that something is in your eyes or under your lids?   0.04 ± 0.29 0.32   0.06 ± 0.24 0.08
Do you experience deep pain in or around your eyes?   0.00 ± 0.21 1.00   0.00 ± 0.21 1.00
have you noticed redness in your eyes?   0.17 ± 0.21 0.01a   0.27 ± 0.49 ,0.01a
Note: aBolded P values represent statistical significance.
Abbreviation: SD, standard deviation.